Inactive Instrument

Endologix, Inc. Stock Nasdaq

Equities

US29266S1069

Medical Equipment, Supplies & Distribution

Dynamic Chart
Endologix LLC Appoints Mike Mathias as Chief Commercial Officer CI
Endologix LLC Announces That Art Taylor Joins Board of Directors CI
Endologix LLC Appoints Scott Ward Joins Board of Directors CI
Endologix LLC Announces Appointment of Scott Ward as Board of Directors CI
Endologix LLC Announces the U. S. Centers for Medicare & Medicaid Services Grants Transitional Pass-Through Payment for the Detour System CI
Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session CI
Endologix Llc Announces the U. S. Centers for Medicare & Medicaid Services Grants New Technology Add-On Payment for the Detour System CI
Endologix LLC Appoints Lucas Buchanan to its Board of Directors CI
Endologix Announces First Patients Treated with the DETOUR?? System, Advancing Treatment for Complex Peripheral Artery Disease CI
Endologix LLC Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting CI
Endologix Llc Receives Fda Approval of the Detour System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with Pad CI
Endologix LLC Announces 150Th Patient Enrolled in JAGUAR Randomized Controlled Trial CI
Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session CI
Endologix LLC Announced the Five-Year Results from the Leopard Randomized Controlled Trial CI
Endologix LLC Announces the Elevate CI
More news
Managers TitleAgeSince
Chief Executive Officer 62 16-11-30
Director of Finance/CFO - -
Chairman 65 20-06-18
Members of the board TitleAgeSince
Chairman 65 20-06-18
Director/Board Member - -
Director/Board Member - -
More insiders
Endologix, Inc. develops, manufactures, markets and sells medical devices for the treatment of aortic disorders. The Company's products are designed for the minimally-invasive endovascular treatment of abdominal aortic aneurysms (AAA). Its AAA products are developed on one of two platforms: traditional minimally-invasive endovascular aneurysm repair (EVAR) or endovascular aneurysm sealing (EVAS), the Company's solution for sealing the aneurysm sac while maintaining blood flow. The Company's EVAR products include the AFX Endovascular AAA System (AFX System), the VELA Proximal Endograft (VELA) and the Ovation Abdominal Stent Graft System (Ovation System). The Company's EVAS product is the Nellix Endovascular Aneurysm Sealing System (the Nellix EVAS System).
More about the company